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Abstract: A topical desiccating wound agent containing methanesulfonic acid, dimethylsulfoxide 
and amorphous silica was evaluated in three in vitro models for its efficacy against biofilms pro-
duced by Pseudomonas aeruginosa (ATCC-15442) and Staphylococcus aureus (ATCC-6538). The in vitro 
biofilm models used were; the MBEC Assay®, Centre for Disease Control (CDC) Biofilm Reactor® 
and a Semi-solid biofilm model. A 30-s exposure of a topical wound desiccating agent was used in 
each model. A complete eradication of viable cells was demonstrated in all models for both strains 
(p < 0.0001). Imaging with scanning electron microscopy (SEM) was performed where possible. All 
three models demonstrated complete eradication of viable cells with a 30 s application of a topical 
wound desiccating agent. 
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1. Introduction 
Chronic non-healing wounds of the lower extremity represent a global burden to the 
healthcare system and are a significant contributor to reduced quality of life and morbid-
ity in affected persons. Chronic wounds have typically been classified based on their un-
derlying aetiology with the most commonly reported in the literature being diabetic foot 
ulcers, venous leg ulcers, Pressure Injuries and non-healing surgical wounds [1]. Despite 
the underlying pathophysiology differing between these types of chronic wounds they 
share some common features; most notably prolonged or excessive inflammation [2], per-
sistent infections [3,4], and the inability of dermal and/or epidermal cells to respond to 
reparative stimuli [5]. 
Over the last decade there has been significant focus on the role of biofilms as causes 
of chronic infections and in contributing to delayed wound healing. Biofilms have collec-
tively been described as “aggregates of microorganisms which may be embedded in a 
protective matrix, may attach to host tissue or in-dwelling medical devices or exist as ag-
gregates in fluids adjacent to those surfaces. In contrast to planktonic microorganisms, 
biofilm associated microorganisms demonstrate aggregation, reduced growth rates and 
altered gene expression” [6]. These changes may help to explain behavioural changes and 
why biofilms can exhibit enhanced tolerance to antimicrobials and the host immune re-
sponse. In chronic non-healing wounds, evidence suggests that biofilms may be present 
in up to 80% of cases [7]. Once pathogenic biofilms become established in host tissue, they 
can drive chronic and persistent infections, which may delay ulcer healing [8]. 
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A significant shift in clinical paradigms has been proposed for the treatment and 
management of wounds with chronic biofilm infections [9,10]. Physical removal and/or 
disruption of biofilms by surgical or conservative sharp debridement form the pillar of 
treatment. However, the spatial distribution of microbial aggregates in tissue [11–13] pre-
sent challenges in ensuring removal, therefore augmenting debridement through the use 
of topical agents (antimicrobial, non-antimicrobial) has been advocated. A limitation with 
using topical agents is the limited robust data on their efficacy in vivo. A recent systematic 
review identified that 90% of all topical wound agents tested for efficacy against biofilm 
were conducted in vitro, using 16 different models [14]. Although there are acknowledged 
limitations of in vitro models, such as the absence of a model which truly mimics a human 
wound, in vitro analysis forms an integral component in screening for potentially benefi-
cial agents. 
In this study, we report on a novel topical wound desiccating agent containing meta-
nesulfonic acid (MSA)-dimethylsulfoxide (DMSO) and amorphous silica (SiO2) and its ef-
ficacy against in vitro biofilms. The use of this gel has been reported in a small case study 
of lower limb ulcers. The manufacturers of the gel solution report that the use of a desic-
cating acid as a wound treatment was investigated based on its antibacterial and denatur-
ation effects, and efficacy in other medical areas [15]. DMSO has historically been used in 
the treatment of ischemic ulcers and scleroderma [16]. We undertook a systematic ap-
proach to testing this agent using three separate in vitro biofilm models. The MBEC As-
say® is a standardised model for allowing rapid screening of agents for antimicrobial in-
hibition and efficacy. The CDC Biofilm Reactor® is a standardised in vitro model capable 
of reproducible biofilms on individual coupons under flow, and the semi-solid model has 
been designed to simulate a wound environment through the growth of bacteria encap-
sulated in agar [17]. 
2. Results 
2.1. Minimum Biofilm Eradication Concentration (MBEC) Assay® 
A 30-s exposure of topical MSA-DMSO gel solution demonstrated complete eradica-
tion of viable cells for American Type Culture Collection (ATCC) Pseudomonas aeruginosa 
(ATCC-15442) and Staphylococcus aureus (ATCC-6538) when compared to untreated con-
trols (Figure 1). This equated to a mean log reduction of 5.55 ± 0.4 Log10 CFU/mm2 for P. 
aeruginosa (p < 0.0001, 95% CI 6.54 to 6.86) and 6.74 ± 1.5 Log10 CFU/mm2 for S. aureus (p < 
0.0001, 95% CI 8.53 to 8.83). Scanning Electron Microscopy (SEM) images of untreated 
control pegs for both P. aeruginosa and S. aureus demonstrate the presence of dense micro-
bial aggregates. In contrast, SEM images of pegs treated for 30 s with topical MSA-DMSO 
gel solution show no microbial aggregates and lysed cells (Figure 2). 




Figure 1. Results for MBEC Assay® for P. aerurinosa (grey bar) and S. aureus (white bar) reported in 
CFUmm2. The error bars are demonstrating standard deviation. The *** demonstrates statistical 
significance of p < 0.0001. 
 
Figure 2. SEM image of P. aeruginosa ATCC-15442 biofilm on a MBEC® peg (A) control at 11,800 magnification and 1 µm 
and (B) treatment with topical MSA gel solution for 30 s at 6,800 magnification and 1 µm. SEM image of S. aureus ATCC-
6538 biofilm on a MBEC® peg (C) control at 11,700 magnification and 1 µm and (D) treatment with topical MSA-DMSO 
gel solution for 30 s at 11,160 magnification and 1 µm. 
2.2. CDC Biofilm Reactor® 
Polycarbonate discs with P. aeruginosa and S. aureus biofilms were exposed to a topi-
cal MSA-DMSO gel solution for 30 s. When compared against untreated controls, coupons 
exposed to topical MSA-DMSO gel solution demonstrated complete eradication of viable 
cells for both P. aeruginosa and S. aureus (Figure 3). This equated to a reduction of greater 
than 8.68 ±0.1 Log10 (p < 0.0001, 95% CI 8.5 to 8.3) for P. aeruginosa and 6.7 ± 0.1 Log10 (p 
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< 0.0001, 95% CI 6.5 to 6.8) for S. aureus. SEM images of P. aeruginosa and S. aureus-un-
treated coupons show dense aggregates surrounded by extracellular matrix (observed in 
P. aeruginosa only) (Figure 4). No microbial aggregates are seen in treated coupons of P. 
aeruginosa biofilm and small aggregates of < 10 bacterial cells are seen in S. aureus-treated 
coupons. 
 
Figure 3. Results from CDC for P. aeruginosa and S. aureus reported in CFU/coupon. The error bars 
are demonstrating standard deviation. The *** demonstrates statistical significance of p < 0.0001. 
 
Figure 4. SEM image of P. aeruginosa ATCC-15442 biofilm on a polycarbonate coupon (A) untreated control at 15,570 
magnification and 1 µm and (B) treatment with topical MSA-DMSO gel solution for 30 s at 1,830 magnification and 1 µm. 
SEM image of S. aureus ATCC-6538 biofilm on a polycarbonate coupon (C) Untreated control at 4,910 magnification and 
2 µm and (D) treatment with topical MSA-DMSO gel solution for 30 s at 13,900 magnification and 1 µm. 
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2.3. Semi Solid Model 
P. aeruginosa and S. aureus biofilms encapsulated in a Wound Simulation Medium 
(WSM) were exposed to a 30 s application to a topical MSA-DMSO gel solution. When 
compared against untreated control media, treated media demonstrated complete eradi-
cation of viable cells for both P. aeruginosa (6.07 ± 0.3 Log10, p < 0.0001, 95% CI 5.7 to 6.3) 
and S. aureus (6.42 ± 0.3 Log10, p < 0.0001, 95% CI 5.4 to 7.4) (Figure 5). 
. 
Figure 5. Results from semi solid model for P. aeuruginosa and S. aureus reported in CFU/mL. The 
error bars are demonstrating standard deviation. The *** demonstrates statistical significance of p < 
0.0001. 
3. Discussion 
In vitro biofilms are commonly (but not always) embedded in a protective, hydrated, 
self-produced exopolymeric matrix that comprises lipids, proteins, eDNA and exopoly-
saccharides [18,19]. Topical agents that induce desiccation through hygroscopy may be 
beneficial as therapies in managing chronic biofilm infections in humans [9] given their 
ability to effectively dehydrate components of biofilm architecture and the microbial cells 
themselves. The agent tested in this series of in vitro models is a novel formulation con-
taining methanesulfonic acid, dimethylsulfoxide and amorphous silica in a gel formula-
tion. The principal action of MSA is its hygroscopicity, a general term used to describe 
materials that readily take up water from their surroundings. This action, when in prox-
imity to planktonic microbial cells, leads to desiccation of the cell membrane lipid bilayer. 
This is one of the primary cellular components affected by variations in hydration level, 
causing changes in lipid packing that may have damaging effects on cell viability [20]. 
There is some limited preliminary research suggesting that desiccation agents may 
be an option to consider in managing chronic wounds with biofilm driven infections [21]. 
Traditional wound care already uses various weak acidic formulations as treatments 
[22,23] as well as honey which possesses hygroscopic abilities resulting in dehydration. 
[21,24,25]. These agents exist at low concentrations and are generally well tolerated with 
low toxicity. There is also evidence to suggest that weak acids could be developed into 
treatments for biofilm infections, with preliminary studies suggesting that these acids may 
eradicate biofilm through penetration of the matrix and cell membrane, which may be a 
similar mechanism to MSA [26]. 
MSA is classified as a strong acid and through its potent hygroscopic action demon-
strated an ability to eradicate all viable cells of both S. aureus and P. aeruginosa in all three 
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models. Although it has demonstrated effects against bacterial cells, there are likely also 
collateral affects to host cells. This has not been investigated as part of this work, and 
safety studies to determine toxicity against host cells are required moving forward. In this 
study, we have made efforts to ensure that the results are meaningful by testing the prod-
uct for the duration it should be used for [27], and testing in a range of models from a 
simple screening tool to a model designed to try and emulate a wound environment. 
This study has several limitations to acknowledge. In vitro studies are not reflective 
of the wound environment [14] and can at best provide indications to progress with fur-
ther research. The models were performed in triplicate and run independently, but were 
not performed in multiple laboratories by independent researchers [28]. These models 
were run as single species, which is not indicative of the polymicrobial nature of chronic 
wounds [29,30] and clinical isolates were not examined. Safety testing for toxicity to host 
cells is required. 
Although these preliminary investigations have produced promising results, signif-
icant further investigation and research is required. The in vitro results indicate that the 
progression of testing and development may be warranted, however extensive safety test-
ing is required to ensure the response on host cells and surrounding tissue is fully under-
stood and the risks identified, particularly with the known cytotoxic actions of MSA 
[31,32]. 
4. Materials and Methods 
4.1. Bacteria 
ATCC strains of P. aeruginosa (ATCC-15442) (Manassas, VA, USA) and S. aureus 
(ATCC-6538) (Manassas, VA, USA) were used independently in all three models. All 
broth and agar plates were manufactured in the laboratory from raw materials purchased 
from Sigma-Aldrich (St. Louis, MI, USA). For the standardised MBEC Assay® and CDC 
biofilm reactor (BioSurface Technologies Corporation, Bozeman, MT, USA) the strains 
were streaked on Tryptone Soy Agar (TSA) plates for 24 h at 37 °C and isolated colonies 
were grown overnight in Tryptone Soy Broth (TSB) at 35 °C and 110  10 rpm. For the 
semi-solid biofilm model, the strains were streaked on Luria-Bertani (LB) Agar plates was 
made as described previously and incubated for 24 h at 37 °C. A single colony was then 
used to inoculate in LB broth which was then incubated overnight at 37 °C and 250 rpm. 
4.2. Test Agent 
Debrichem® (DebX Medical, Amsterdam, The Netherlands) is a topical gel solution 
with the principal agent being methanesulfonic acid (MSA). MSA acidity is buffered by 
the use of dimethylsulfoxide (DMSO) and amorphous silica (SiO2). The final concentration 
is 83% MSA and 13.8% DMSO. The gel contains a red dye (1-(p-Nitrophenylazo)-2-naph-
thol, 1-(4-Nitrophenylazo)-2-naphthol, also known as Para Red) in order to better define 
the product application on the wound and the surrounding skin. Debrichem is applied 
topically to the wound bed and the recommended time of application by the manufacturer 
is 60 s, after which the area is flushed with saline, to cease the action of the acid. For these 
in vitro experiments, an exposure time of 30 s was selected to 1; ensure application that 
was less than the maximum application time and 2; to determine if a shorter period of 
exposure then the currently recommended time provide efficacious. All products used in 
this study were prepared by DebX Medical, Netherlands. 
4.3. In vitro Biofilm Models 
All testing was performed in triplicate on two independent occasions. 
4.4. MBEC Assay® 
MBEC Assay® testing was completed according to the ASTM International Standard 
Test Method for Testing Disinfectant Efficacy against P. aeruginosa Biofilm using the 
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MBEC Assay® [33]. Briefly, an overnight suspension of each test strain was diluted to 2 × 
107 CFU/mL and 1 × 107 CFU/mL for P. aeruginosa and S. aureus, respectively. A total of 
150 µL of each inoculum was added to a 96-well plate (MBEC Assay®, Innovotech, Ed-
monton, AB, Canada), and the 96-peg lid was then inserted onto the plate and incubated 
for 24 h at 35 ± 2 °C with continuous shaking (110 ± 10 rpm). 
Biofilm pegs were washed in sterile saline (NaCl 0.9%) for 10 s, then transferred to a 
new 96-well plate containing 200 µL of either MSA-DMSO solution or sterile saline (con-
trol) for a contact-exposure time of 30 s. Following treatment, the pegs were rinsed twice 
in saline for 10 s each. At this point, pegs for imaging were removed and fixed in a 4% 
Glutaraldehyde solution overnight at 4 °C. To facilitate the disaggregation of the biofilm, 
the recovery plate was sonicated in an ultrasonic water bath (SoniClean™ 160TD, Stepney 
Australia) on high for 30 min. The recovery solution was then serially diluted, and spot 
plated in triplicate onto TSA plates and incubated at 35 ± 2 °C for 18–24 h for plate counts 
and quantitative analysis. In total, nine pegs on each occasion were treated with MSA-
DMSO solution for quantification analysis (6 pegs) and SEM imaging (3 pegs), with the 
same number of control pegs treated with sterile saline (NaCl 0.9%). 
4.5. CDC Biofilm Reactor® Model 
The CDC Biofilm reactor® (BioSurface Technologies Corporation, Bozeman, MT, 
USA) was prepared using the ASTM Method E3161-18 ‘Standard practice for preparing a 
P. aeruginosa or S. aureus Biofilm using the CDC Biofilm Reactor’ [34], and the effect of 
MSA-DMSO was determined using the ASTM Method E2871-19 ‘Standard Test Method 
for Determining Disinfectant Efficacy Against Biofilm Grown in the CDC Biofilm Reactor 
Using the Single Tube Method’20. Briefly, an overnight culture of P. aeruginosa was di-
luted to 2 × 107 CFU/mL, then 1 mL was added to the CDC reactor containing 500 mL 
sterile 300 mg/L TSB. The reactor was placed on a magnetic stir plate (Talboys™ 4 × 4 
Ceramic Stirrer 230 V, USA) at 125 ± 5 r/min at room temperature for a 24-h batch phase 
growth. A growth medium (100 mg/L TSB) was then added during the continuously 
stirred tank reactor (CSTR) phase with a residence time of 30 ± 2 min, using a Digital Pump 
(Masterflex Digital Drive and Pump Head, Vernon Hills, IL, USA) for a further 24 h. 
For S. aureus, an overnight culture was diluted to 1.2 × 107 CFU/mL before being 
added to the reactor containing 500 mL of sterile 3 g/L TSB solution. The reactor was 
placed on the magnetic stir plate at 60 ± 5 r/min and incubated at 36 ± 2 °C for 24 h of batch 
phase growth. The CSTR phase was then run for an additional 24 h at 36 ± 2 °C using 1 
g/L TSB, with a residence time of 30 ± 2 min. 
Biofilm coupons of both strains were rinsed in a 50 mL conical centrifuge tube con-
taining 30 mL 0.9% saline. Four coupons were dropped into individual centrifuge tubes 
containing 4 mL of MSA-DMSO gel solution for 30 s ensuring even coating of the coupons. 
Control coupons underwent the same treatment process with sterile saline. The coupons 
stored for imaging were rinsed in 0.9% saline and fixed in 4% Glutaraldehyde solution 
overnight. Coupons for quantification were then rinsed in a tube containing 10 mL of 0.9% 
saline and dropped into a new tube containing 36 mL of 0.9% saline. Each tube was then 
vortexed on the highest setting for 30 ± 5 s at room temperature and then placed in an 
ultrasonic water bath (SoniClean™, Stepney, South Australia, Australia) at 45 ± 5 kHz for 
30 ± 5 s at room temperature. This process was repeated for a total of 3 × rounds of vor-
texing and 2 × rounds of sonication. For the treated coupons, the entire recovery solution 
was processed through a Nalgene Reusable Filter Unit with a 0.2 µm filter, with the filter 
membrane then being placed directly onto a TSA plate. The control coupon tubes were 
briefly vortexed and diluted from 100 to 106 and plated in duplicate using the spread plate 
method on TSA. The plates were then incubated at 35 C for 48 h and 72 h for the control 
and treated plates, respectively. 
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4.6. Semi Solid Biofilm Model 
The semi-solid model has been previously described by Cone et al. [17]. It simulates 
a wound environment through the growth of bacteria encapsulated in agar. 
Briefly, Wound Simulation Medium (WSM) was prepared for a final concentration 
of; 5 mL Bolton Broth with 1% agar, mixed with 2.5 mL of both bovine fetal serum (Sigma-
Aldrich, St Louis, MI, USA) and defibrinated horse blood (Australian Ethical Biologicals, 
VIC, Australia). Overnight cultures of each strain were grown in LBB and diluted to a final 
dilution of 10−4 in WSM. The semi solid model was assembled by adding WSM to the 
centre of a gene frame (Thermofisher Scientific, Waltham, MA, USA) adhered to a glass 
microscope slide (26 mm × 76 mm). The medium was allowed to set before 2 µL of the P. 
aeruginosa and 4 µL of the S. aureus inoculum were added to the centre of the medium. 
Additional WSM was added to encapsulate the inoculum and allowed to set. The slides 
were then placed in a sterile container with moist tissue paper before being sealed with 
Parafilm and incubated at 37 C for 24 h. 
Following incubation, 150 µL of MSA-DMSO gel solution was pipetted over the mid-
dle of the slide for 30 s, before being rinsed off with approximately 3 mL of sterile saline. 
Control slides were rinsed with sterile saline. Each gel was then aseptically transferred to 
a 2 mL Eppendorf tube containing 1.5 mL of sterile saline and a 5 mm stainless steel bead. 
The tubes then underwent bead beating in a TissueLyser II (Qiagen, Hilden, Germany) at 
20 Hz for 15 s to break up the agar. Following bead beating, the contents of each tube were 
transferred to 45 mL of 0.9% saline and centrifuged at maximum speed (6000× g) for 10 
min. Following centrifuging, the supernatant was carefully decanted, and the process re-
peated. All but 2 mL of the supernatant was removed, which was used to resuspend the 
pellet through vortexing the tube at a low speed. The tubes were then placed in the ultra-
sonic water bath (SoniClean™, Stepney, South Australia) and degassed for 5 min, fol-
lowed by sonication on high for 5 min. Each solution was then serially diluted from 100 to 
106 in saline, and spot plated in triplicate on LBA plates. The plates were then incubated 
at 37 ± 2 °C for 18–24 h and colony counted. 
4.7. Confirmation of Biofilm Growth through Scanning Electron Microscopy (SEM) 
SEMwas performed with the LSM 880 confocal microscope (Carl Zeiss, Oberkochen, 
Germany) to visualise and confirm the growth of bacterial biofilms on the MBEC Assay® 
pegs and CDC biofilm reactor® polycarbonate discs. Bacterial biofilms were sampled at 5–
200 µm with a random field selection. Fixed specimens were dehydrated through serial 
dilutions of ethanol and hexamethyldisilazane (HDMS) (Polysciences, Inc., Warrington 
PA, USA). Coupons were rinsed twice in phosphate buffered saline (PBS) then underwent 
a 50% ethanol and saline wash, 70% ethanol, 95% and two 100% ethanol washes. They 
were then washed in 2:1 ethanol and HMDS, 1:1, 1:2 ethanol and HMDS and finally two 
100% HMDS washes. Coupons were then air dried in the fume hood for at least 48 h. They 
were then mounted, gold coated for 60 s at a current of 60 mA and examined. 
4.8. Statistics 
Unpaired two-tailed t tests were used to compare individual treatments with the con-
trol. Data are given as mean, median, and standard deviation (±). Data were analysed 
through Statistical Package for Social Sciences Version 25 (IBM Corp., Armonk, NY, USA). 
Data were Log transformed before statistical analyses were performed. 
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